孕激素与GnRH类似物在辅助生殖促排卵中垂体抑制的系统综述与meta分析
该系统综述与meta分析纳入7项比较性研究共2047名女性,比较孕激素与GnRH拮抗剂或短效GnRH激动剂方案在辅助生殖促排卵中的垂体抑制效果。主要结局为每名女性的活产率,孕激素与GnRH拮抗剂在有效性和安全性上相似;与短效GnRH激动剂方案相比,孕激素方案每胚胎移植的活产或持续妊娠率显著更高(RR 1.49,95%CI 1.16至1.91)。
要点
- 孕激素与GnRH拮抗剂在有效性和安全性参数上相似。
- 与短效GnRH激动剂相比,孕激素方案每胚胎移植活产或持续妊娠率更高(RR 1.49)。
- 孕激素方案刺激时间更长、促性腺激素用量更多,但差异临床可忽略。
核心结论
- 孕激素可有效防止辅助生殖技术周期中的提前排卵。
- 若更大规模、设计良好的研究证实,在因医学指征不计划新鲜胚胎移植时,孕激素可能成为GnRH类似物的有效且低成本替代方案。
研究设计与样本
- 系统综述与meta分析,纳入7项比较性研究,共2047名女性。
- 3项研究比较孕激素与GnRH拮抗剂,4项研究比较孕激素与GnRH激动剂。
- 采用GRADE系统评估证据质量。
- 多数研究为非随机研究,且报告每胚胎移植结局而非每名女性结局。
主要发现
- 孕激素与GnRH拮抗剂在有效性和安全性参数上相似。
- 与短效GnRH激动剂方案相比,孕激素与每胚胎移植活产或持续妊娠显著更高相关(RR 1.49,95%CI 1.16至1.91)。
- 孕激素方案刺激持续时间显著更长(均数差0.61天,95%CI 0.33至0.89)。
- 孕激素方案促性腺激素用量显著更多(均数差433.2 IU,95%CI 311.11至555.19)。
- 孕激素与GnRH激动剂之间的安全性参数相似。
关键数值与推荐
- 主要结局为每名女性的活产率。
- 次要结局包括每名女性和每胚胎移植的活产或持续妊娠、持续妊娠、临床妊娠、卵母细胞数和减数第二次分裂中期卵母细胞数、刺激持续时间和促性腺激素消耗量。
- 不良事件包括流产、异位妊娠和多胎妊娠率。
临床怎么用
- 孕激素可用于辅助生殖技术周期中的垂体抑制,防止提前排卵。
- 在因医学指征不计划新鲜胚胎移植时,可考虑将孕激素作为GnRH类似物的低成本替代选择。
- 需注意孕激素方案刺激时间略长、促性腺激素用量略多,但差异临床可忽略。
局限性
- 多数纳入研究为非随机研究。
- 多数研究报告每胚胎移植结局而非每名女性结局。
- 证据质量需结合GRADE评估结果谨慎解读,结论有待更大规模、设计良好的研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This systematic review and meta-analysis of comparative studies investigated whether progestins are as effective as gonadotrophin releasing hormone (GnRH) analogues for pituitary suppression in assisted reproduction. The primary outcome was live birth rate per woman. Secondary outcomes were live birth or ongoing pregnancy per woman and per embryo transfer, ongoing pregnancy, clinical pregnancy, numbers of oocytes and metaphase-two oocytes, duration of stimulation and gonadotrophin consumption. Adverse events included miscarriage, ectopic pregnancy and multiple pregnancy rates. The GRADE system was used to assess the quality of evidence. Seven studies involving a total of 2047 women were included. Three studies compared a progestin with a GnRH antagonist and four studies compared a progestin with a GnRH agonist. Most studies are non-randomized and report outcomes per embryo transfer, rather than per woman. Although progestins were similar to GnRH antagonists in effectiveness and safety parameters, they were associated with significantly higher live birth or ongoing pregnancy per embryo transfer compared with the short GnRH agonist protocol (RR 1.49, 95% CI 1.16 to 1.91). Progestin primed stimulation lasted significantly longer (mean difference 0.61 days, 95% CI 0.33 to 0.89) and required significantly more gonadotrophins (mean difference 433.2 IU, 95% CI 311.11 to 555.19) than the short GnRH agonist protocol, but the differences were clinically negligible. Safety parameters were similar between progestins and GnRH agonists. In conclusion, progestins can effectively prevent premature ovulation in assisted reproductive technology cycles. If larger and well-designed studies confirm these findings, progestins may be an effective and low-cost alternative to GnRH analogues when a fresh embryo transfer is not planned owing to a medical indication.
引用
- Alexandru P, Cekic SG, Yildiz S, et al. Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis. Reprod Biomed Online. 2020. PMID: 32327297. doi:10.1016/j.rbmo.2020.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。